PROM1 and neoplasm: Finally, we synthesized a CD133-targetingradioimmunoconjugate labeled with the positron-emitting radiometalzirconium-89 (t1/2 ∼ 3.3 day)—[89Zr]Zr-DFO-αCD133—and performed pilot immunoPETexperiments in a subcutaneous xenograft model of SCLC that demonstratedthe selective uptake of the probe in tumor tissue.